ID: ALA4286890

Max Phase: Preclinical

Molecular Formula: C21H16N4O5

Molecular Weight: 404.38

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)c1ccc(Nc2ccc([N+](=O)[O-])c3nonc23)c(-c2ccc(C)cc2)c1

Standard InChI:  InChI=1S/C21H16N4O5/c1-12-3-5-13(6-4-12)15-11-14(21(26)29-2)7-8-16(15)22-17-9-10-18(25(27)28)20-19(17)23-30-24-20/h3-11,22H,1-2H3

Standard InChI Key:  RQIVQXFEBIUJQL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 404.38

Molecular Weight (Monoisotopic): 404.1121

AlogP: 4.64

#Rotatable Bonds: 5

Polar Surface Area: 120.39

Molecular Species: NEUTRAL

HBA: 8

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.91

CX Basic pKa:

CX LogP: 4.87

CX LogD: 4.87

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.29

Np Likeness Score: -1.14

References

1. Wiedemann B, Weisner J, Rauh D..  (2018)  Chemical modulation of transcription factors.,  9  (8): [PMID:30151079] [10.1039/C8MD00273H]

2.  (2014)  Potent analogues of the c-myc inhibitor 10074-g5 with improved cell permeability, 

3. Ross J, Miron CE, Plescia J, Laplante P, McBride K, Moitessier N, Möröy T..  (2021)  Targeting MYC: From understanding its biology to drug discovery.,  213  [PMID:33460833] [10.1016/j.ejmech.2020.113137]

4. Mancini RS, Barden CJ, Weaver DF, Reed MA..  (2021)  Furazans in Medicinal Chemistry.,  64  (4.0): [PMID:33569941] [10.1021/acs.jmedchem.0c01901]

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data